Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding.

Bin L, Thorburn J, Thomas LR, Clark PE, Humphreys R, Thorburn A
J Biol Chem. 2007 282 (38): 28189-94

PMID: 17666396 · DOI:10.1074/jbc.M704210200

MeSH Terms (14)

Binding, Competitive Cell Line, Tumor Dose-Response Relationship, Drug Electroporation Gene Expression Regulation, Neoplastic Humans Ligands Models, Biological Mutation Neoplasms Protein Binding Receptors, TNF-Related Apoptosis-Inducing Ligand Signal Transduction Subcellular Fractions

Connections (1)

This publication is referenced by other Labnodes entities: